Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eczema drug interaction study completed: how rocatinlimab affects other medications

NCT ID NCT05891119

First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 26 times

Summary

This early-phase study looked at how rocatinlimab, a potential new treatment for moderate to severe eczema (atopic dermatitis), interacts with other common drugs. 21 adults with eczema took part. The goal was to measure drug levels in the blood and check for side effects, helping doctors understand if dose adjustments are needed when rocatinlimab is used with other medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Accel Research Sites (ACR)

    DeLand, Florida, 32720-3134, United States

  • Axis Clinicals, LCC

    Dilworth, Minnesota, 56529, United States

  • DermDox Dermatology Centers, PC - Camp Hill

    Camp Hill, Pennsylvania, 17011, United States

  • DermDox Dermatology Centers, PC - Sugarloaf

    Nashville, Tennessee, 37203-1632, United States

  • Direct Helpers Research Center (DHRC)

    Hialeah, Florida, 33012-3618, United States

  • Velocity Clinical Research -Spartanburg

    Spartanburg, South Carolina, 29303-4225, United States

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California, 91606-1570, United States

Conditions

Explore the condition pages connected to this study.